TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01952067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: line-to-line reaming and cementing technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard over-reaming with 2 broach sizes
Study: NCT03556956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Tyrosine kinase inhibitor
Study: NCT00883064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
Study: NCT00355303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGE2 gel
Description: PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
Study: NCT02180243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation/Acupuncture
Description: Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
Study: NCT02180243

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gulf War Health Education
Description: Participants randomized to this group will take part in a health education group.
Study: NCT02459002

Intervention type: BEHAVIORAL
Intervention: QOL Questionnaire
Description: Participant outcomes assessed with survey

Intervention type: BEHAVIORAL
Intervention: QOL Questionnaire
Description: Participant outcomes assessed with survey

Intervention type: BEHAVIORAL
Intervention: Caregiver Satisfaction Questionnaire
Description: Caregiver satisfaction with quality of care assessed with surveys
Study: NCT02228759

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block
Description: All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
Study: NCT03369171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myo Armband (MYO,Thalamic Labs Inc, Kitchener, ON, Canada)
Description: MYO armband is a commercialized, gesture control device containing Height Medical Grade Stainless Steel EMG sensors, and an inertial measurement unit (IMU) consisting of a three-axis gyroscope and a, three-axis accelerometer, three-axis magnetometer. MY0 motion data (EMG and IMU) will be recorded during standard motor/neurological evaluation.~The clinical assessment will include standard motor neurological evaluation : EDSS and FS, walking status, foot tapping test, Heel-knee test, finger tapping test, Finger to nose test, Romberg test, timed 25 foot walk test, nine holes peg test. This clinical assessment will be done at the inclusion visit (V1) and at the follow-up visit at one year (V2).
Study: NCT00972660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell (MSC)
Description: Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).~Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone and cyclosporine or primary therapies
Description: Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus~Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)
Study: NCT01305239

Intervention type: DRUG
Intervention: Aromasin
Description: Aromasin 25 mg daily.
Study: NCT00556465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg of effervescent N-acetylcysteine tablet twice per day for three months
Study: NCT02892227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmitral flow estimation
Description: Estimation of the transmitral flow of the inferior vena cava and its variations
Study: NCT01638143

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MenaQ7 M-1500 capsules
Description: The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gnosis P-1000 capsules
Description: The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gnosis P-1000 capsules
Description: The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gnosis M-1500 capsules
Description: The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~* MenaQ7 M-1500 capsule~* Gnosis P-1000 capsule~* Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks.
Study: NCT00044798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Participants will receive 15 treatments of rTMS over 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS
Description: Participants will receive 15 treatments of sham rTMS over 3 weeks.
Study: NCT00743977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenazopyridine HCl
Description: 100mg tablet in fasting state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine HCl
Description: 100mg tablet in fasting state
Study: NCT02163005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: -agent will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agent to assess its feasibility as an alternative to Iodine based contrast agents.
Study: NCT02630589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory brainstem implant
Description: The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
Study: NCT03501602

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA protector
Description: In this arm the LMA protector will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel LMA
Description: In this arm the I-gel LMA will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
Study: NCT01383564

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP group
Description: Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non CPAP group
Description: Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
Study: NCT01593475

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by CCRT
Description: Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively.
Study: NCT04235153

Intervention type: OTHER
Intervention: Evaluation of the 9 dimensions of the CANUT-QVA questionnaire
Description: Evaluation of the contribution of a new questionnaire by patients with solid or hematological cancer according to 9 dimensions:~1. Making food~2. Place where the meals are eaten~3. Eating and drinking: Nutrition~4. Eating and drinking: The pleasure of tasting, chewing~5. Eating and drinking: Satiated, well being~6. Food preparation: Supply, choice, presentation~7. Eating and drinking: Feelings~8. After eating: heaviness, discomfort, hunger~9. Taste/Odour Problems to confirm the number and structure of factors obtained at the end of the pre-study and to remove redundant questions.
Study: NCT04408703

Intervention type: DIAGNOSTIC_TEST
Intervention: Red Density
Description: Image analysis of endoscopic images in patients with ulcerative colitis
Study: NCT04276753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Terminalia Chebula Fruit Extract
Description: Standardized fruit extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03101839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4785
Description: KRAS Antisense Oligonucleotide
Study: NCT02167009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres
Description: Embosphere Microspheres are indicated for use in embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
Study: NCT02751268

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
Study: NCT00506441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
Study: NCT03656172

Intervention type: BIOLOGICAL
Intervention: Haemoglobin measure
Description: Haemoglobin measure before and one month after standard iron treatment
Study: NCT03977181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Community Health Club
Description: GBHCs will be facilitated by trained Lay Health Counsellors (LHC). GBHCs will consist of a maximum 20 participants. GBHC sessions will held multiple times a month in each study area, allowing for flexibility for study participants. Sessions will be held at a safe and secure, centrally located area within the study community, and will be regularly monitored and assessed by the study coordinator. Participants will be invited to join a club-specific WhatsApp group to facilitate group communication and adherence support throughout the month. They will also be invited to partner up with another participant to provide mutual peer support. Permission will be sought from group-based adherence support participants before they are added to WhatsApp groups. Group adherence counsellors assigned will be members of WhatsApp groups, and will monitor all shared content to ensure that no inappropriate content or private information is shared in the group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual-based Adherence Support
Description: IAS participants will be matched to a LHC and will schedule IAS sessions once-a-month for the duration of the study. These sessions will be held at a centralized location within the study community. The sessions will be semi-structured to allow for participant-driven discussion of any adherence challenges and key-messages. The adherence curriculum will also explore motivations for PrEP and adherence and focus on practical adherence tips, environmental cues, integration of PrEP within daily routines, short-term goal-setting, problem-solving, safe PrEP disclosure and social support, risk reduction counselling, partner communication, and HIV risk perception. A subset of IAS sessions will be audio-recorded for quality assurance by investigators and the study coordinator. These recordings are for training purposes only and will not form part of the dataset. Consent for recording IAS sessions will be sought from participants during the pre-enrolment consent process.
Study: NCT02506075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranical direct current stimulator
Description: approved by Conformity European as safe treatment device for stroke patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranical direct current stimulator
Description: approved by Conformity European as safe treatment device for stroke patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual inattention training
Study: NCT01192321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric T3 - T9
Description: Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal
Description: Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
Study: NCT02979964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Study: NCT02187783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
Study: NCT02262780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of telmisartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ
Study: NCT02697071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
Study: NCT02163161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF- 04965842
Description: Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
Study: NCT01690663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: placebo
Study: NCT04263259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification
Description: Mobile-Delivered Cognitive Retraining Intervention
Study: NCT02844166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: viscoelastic surface support
Description: Patients will be placed in an ICU bed with viscoelastic surface support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pyramidal foam surface support
Description: Patients will be placed in an ICU bed with pyramidal foam surface support
Study: NCT01133548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel 1.62%
Description: 5 grams administered using an application Site Rotation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel 1.62%
Description: 5 grams administered using an a combination of Application sites
Study: NCT03087864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg i.v. day 1-22-43-64-85

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 23 x 1.8 Gy
Description: Radiotherapy
Study: NCT04541355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hearing Handicap Inventory for Adults - Screening
Description: Patient self-assessment questionnaire to measure probability of hearing impairment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be delivered according to the standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV
Study: NCT00269152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m\^2, intravenous (IV), every 21 days x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: area under the curve (AUC) 5 milligrams per milliliter\*minute (mg/ml\*min), intravenous (IV), every 21 days x 4 cycles
Study: NCT02506075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual inattention training
Study: NCT03518567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoked marijuana cigarettes: High THC dose (6% THC)
Description: Smoked marijuana cigarettes (High THC dose \[6% THC\])
Study: NCT01018238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
Study: NCT04206202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-Printed Patient-Specific Intramedullary Guide
Description: The 3D-printed patient-specific intramedullary guide is used in TKA to control femoral component rotation.